Gelatin Capsule Shell Cross-Linking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gelatin Capsule Shell Cross-Linking
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 62-68

Conclusion

Gelatin capsule shell cross-linking is a common problem for a capsule formulation during stress or stability studies at accelerated storage conditions. Switching the stressed capsule shells and blends with fresh ones can easily prove that the shells are the cause of slowed dissolution. SLS deactivates pepsin despite its advantages and wide use as a surfactant. However, stepwise addition of pepsin and SLS respectively enables each agent to take effect separately. Therefore, SLS need not be abandoned during dissolution method development for gelatin capsule formulations.

Acknowledgment

The authors are grateful to Chris Connolly, manager of analytical development; Jack Chen, supervisor of analytical development; and Andy Cleaver, supervisor of analytical development, for coordinating tasks. We are also grateful to Wendy Liu, chemist in analytical development, for conducting dissolution tests, and Rajeev Bhatnagar, senior technical project lead, for providing fresh capsule blends.

Xiling Song* is senior research associate, Yong Cui is scientist, and Minli Xie is senior scientist, all at Small Molecule Pharmaceutical Sciences, Genentech, 1 DNA Way, South San Francisco, CA 94080,
*To whom all correspondence should be addressed. Submitted: Nov. 10, 2010. Accepted: Feb. 7, 2011

References

1. S. Singh, R. Manikandan, and S. Singh, Pharm. Technol. 24 (5), 58–72, (May 2000).

2. K.S. Murthy, N.A. Enders, and M.B. Fawzi, Pharm. Technol. 13 (3), 72–86 (1989).

3. K.S. Murthy, R.G. reisch, Jr., and M.B. Fawzi, Pharm. Technol, 13 (6), 53–58 (1989).

4. S. Singh et al., Pharm. Technol. 26 (4) 36–58, (2002).

5. USP33–NF28 (US Pharmacopeial Convention, Rockville, MD, 2010), p. 719.

6. M.F.S. Whisler, J. S. Staton, and R. B. DePrince, poster presentation at AAPS conference (New Orleans, LA, 1999).

Citation: When referring to this article, please cite it as "X.Song, Y.Cui, M.Xie, "Gelatin Capsule Shell Cross Linking," Pharmaceutical Technology 35 (5) 62–68 (2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here